(IN BRIEF) Boehringer Ingelheim and LEO Pharma have agreed on a global license and transfer deal for SPEVIGO® (spesolimab), an antibody that blocks the IL‑36 receptor to treat generalized pustular psoriasis (GPP). LEO Pharma will assume worldwide commercialization and clinical development, harnessing … Read the full press release →
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Christophe Bourdon, clinical development, commercialization, Dermatology, EUR 90 million, generalized pustular psoriasis, global license, GPP, IL‑36 receptor, LEO Pharma, monoclonal antibody, partnership, rare skin disease, Shashank Deshpande, spesolimab, SPEVIGO